Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases
نویسندگان
چکیده
منابع مشابه
Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling.
Caveolin-1 (Cav-1) is highly expressed in normal osteoblasts. This article reports that Cav-1 down-regulation is part of osteoblast transformation and osteosarcoma progression and validates its role as oncosuppressor in human osteosarcoma. A survey of 6-year follow-up indicates a better overall survival for osteosarcoma expressing a level of Cav-1 similar to osteoblasts. However, the majority o...
متن کاملIntegrin engagement suppresses RhoA activity via a c-Src-dependent mechanism
The Rho family GTPases Cdc42, Rac1 and RhoA control many of the changes in the actin cytoskeleton that are triggered when growth factor receptors and integrins bind their ligands [1] [2]. Rac1 and Cdc42 stimulate the formation of protrusive structures such as membrane ruffles, lamellipodia and filopodia. RhoA regulates contractility and assembly of actin stress fibers and focal adhesions. Altho...
متن کاملA Novel Function For 12-Lipoxygenase In C-Met And Integrin β4 Axis Crosstalk
___________________________________________________________________161 Autobiographical Statement____________________________________________________163
متن کاملIntegrin-mediated invasion of Staphylococcus aureus into human cells requires Src family protein-tyrosine kinases.
Staphylococcus aureus, a common cause of nosocomial infections, is able to invade eukaryotic cells by indirectly engaging beta1 integrin-containing host receptors, whereas non-pathogenic Staphylococcus carnosus is not invasive. Here, we identify intracellular signals involved in integrin-initiated internalization of S. aureus. In particular, the host cell actin cytoskeleton and Src family prote...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncogene
سال: 2005
ISSN: 0950-9232,1476-5594
DOI: 10.1038/sj.onc.1209269